Eli Lilly and Company traded as low as $718.81 and last traded at $718.89. Approximately 663,002 shares changed hands during trading, a decline of 80% from the average daily volume of 3,354,701 ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...

Eli Lilly says it could pull tens of millions of dollars invested in Australian clinical trials unless the federal government dramatically cuts the time it takes to put new drugs onto the ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country that is ...

Doctors field hundreds of calls about Mounjaro availability Patients now have alternatives to overseas, black market Entry gives Lilly edge over Novo Nordisk in huge market Sign up here.

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY ... A month’s supply of a 10 mg Zepbound pen will run you over $1,000 ...

Access our full analysis report here, it’s free. Branded Pharmaceuticals company Eli Lilly (NYSE:LLY) fell 6.8%. Is now the time to buy Eli Lilly? Access our full analysis report here ...

The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative ...

“Semaglutide generics will be priced almost 95% lower than [Eli Lilly'] current price,” said Vishal Manchanda, senior vice-president, institutional research at Systematix Group. With the drop ...

Lilly beats Novo Nordisk to launch weight-loss drug in India Mounjaro's 5 mg vial priced at around $50, 2.5 mg at about $40 Drug's pricing may limit accessibility in India, analyst says Novo's ...

Eli Lilly has emerged as a popular growth stock thanks to its strength in the weight loss space. But the pharma giant also has an enormous opportunity in the Alzheimer's Disease market.

ATLANTA, April 11, 2025 /PRNewswire/ -- On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response.